ISBN: 9783848752218 - fto (freedom to operate) in the pharmaceutical industry (5 résultats)

paperback. Etat : New. 1st.

Kartoniert / Broschiert. Etat : New. FTO licensing in the pharmaceutical industry deserves special consideration because of the large economic scale of the market, expensive cost of R&D, extremely low success rate, and easy duplication of the drug. Taking these unique aspects into considerati.

Taschenbuch. Etat : Neu. FTO (Freedom to Operate) in the Pharmaceutical Industry | Hirotaka Nonaka | Taschenbuch | 63 S. | Englisch | 2018 | Nomos | EAN 9783848752218 | Verantwortliche Person für die EU: Nomos Verlagsgesellschaft mbH & Co. KG, Waldseestr. 3-5, 76530 Baden-Baden, nomos[at]nomos[dot]de | Anbieter: preigu. …

Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -FTO licensing in the pharmaceutical industry deserves special consideration because of the large economic scale of the market, expensive cost of R&D, extremely low success rate, and easy duplication of the drug. Taking these unique aspects into consideration, the author first explaines how to perform a good FTO search and conclude an appropriate FTO licensing agreement, and then points out two issues; (i) the issue of FTO licensing and EU competition, especially the unreasonable application of the Guideline, and (ii) the issue of FTO licensing and differentiating between a bio venture company and a pharmaceutical company. Solutions for these issues are proposed.The author is Hirotaka Nonaka; an attorney-at-law and patent attorney in Tokyo, Japan, handling particularly IP-related disputes and consulting. 63 pp. Englisch.…

Taschenbuch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - FTO licensing in the pharmaceutical industry deserves special consideration because of the large economic scale of the market, expensive cost of R&D, extremely low success rate, and easy duplication of the drug. Taking these unique aspects into consideration, the author first explaines how to perform a good FTO search and conclude an appropriate FTO licensing agreement, and then points out two issues; (i) the issue of FTO licensing and EU competition, especially the unreasonable application of the Guideline, and (ii) the issue of FTO licensing and differentiating between a bio venture company and a pharmaceutical company. Solutions for these issues are proposed.The author is Hirotaka Nonaka; an attorney-at-law and patent attorney in Tokyo, Japan, handling particularly IP-related disputes and consulting. …